Pulmonary Embolism in Ischemic Stroke: Clinical Presentation, Risk Factors, and Outcome

Jitphapa Pongmoragot, MD; Alejandro A. Rabinstein, MD; Yongchai Nilanont, MD; Richard H. Swartz, MD, PhD, FRCPC; Limei Zhou, PhD; Gustavo Saposnik, MD, MSc, FAHA, FRCPC; On behalf of the Investigators of the Registry of the Canadian Stroke Network (RCSN) and University of Toronto Stroke Program for the Stroke Outcomes Research Canada (SORCan [www.sorcan.ca]) Working Group

Background—Limited information is available on the frequency of pulmonary embolism (PE) in patients with an acute ischemic stroke (AIS). We evaluated clinical characteristics, predisposing factors, and outcomes in AIS patients with PE.

Methods and Results—We included all AIS patients admitted to participating institutions in the Registry of the Canadian Stroke Network. Clinically PE was documented by a physician and confirmed by computed tomography pulmonary angiography within 30 days of the stroke case index. The primary outcome was death or disability at discharge. Secondary outcomes included disposition, length of hospital stay, mortality at 3 months and 1 year. Among 11 287 patients with AIS, PE was found in 89 (0.78%) patients. History of cancer, deep vein thrombosis (DVT)/PE, and DVT during the hospitalization were associated with PE. PE was associated with higher risk of death at 30 days (25.8% versus 13.6%; *P*<0.001), at 1 year (47.2% versus 24.6%; *P*<0.001), and disability at discharge (85.4% versus 63.6%; *P*<0.001). Mean length of stay was longer in stroke patients with PE (36 versus 16 days; *P*=0.001). After adjusting for age, sex, and stroke severity, PE remained associated with lower survival at 30 days and 1 year, and death or disability at discharge (OR 3.02; 95% CI 1.56 to 5.83).

Conclusions—In this large cohort study, PE occurred in nearly 1% of AIS patients. PE was more common in patients with severe stroke, history of cancer, previous DVT/PE or acute DVT and associated with lower short- and long-term survival, greater disability, and longer length of stay. (*J Am Heart Assoc*. 2013;2:e000372 doi: 10.1161/JAHA.113.000372)

Key Words: cerebral infarction • pulmonary embolism • stroke • venous thromboembolism

Stroke is a leading cause of death and disability. Medical complications after ischemic stroke contribute substantially to poor stroke outcomes.[1–6] Pulmonary embolism (PE) is a serious medical condition with an annual incidence rate of 0.50 to 0.69 per 1000 persons in the general population.[7,8]

From the Stroke Outcomes Research Center, Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada (J.P., G.S.); Sunnybrook Hospital, Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada (R.H.S.); Institute of Health Policy, Management and Evaluation (iHPME), University of Toronto, Ontario, Canada (G.S.); Department of Neurology, Mayo Clinic, Rochester, MN (A.A.R.); Siriraj Hospital, Division of Neurology, Department of Medicine, Mahidol University, Bangkok, Thailand (Y.N.); Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada (L.Z.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada (G.S.).

Correspondence to: Gustavo Saposnik, MD, MSc, FAHA, FRCPC, Stroke Outcomes Research Center, Department of Medicine, St. Michael's Hospital, University of Toronto, 55 Queen St E, Toronto, Ontario, Canada M5C 1R6. E-mail: saposnikg@smh.ca

Received July 20, 2013; accepted September 23, 2013.

PE carries a high mortality with case fatality at 3 months ranging between 8.6% and 17%.[9,10] Longer-term mortality can be as high as 24%.[11] The risk of PE, including fatal cases, in patients with acute ischemic stroke (AIS) is well known but insufficiently examined.[3,12] Studies of in-hospital complications after stroke have often used the combined category of venous thromboembolism (VTE), thus grouping PE with deep venous thrombosis (DVT).[13] In the general medical population, immobility, older age, smoking, hypertension, thrombophilia, and cancer are commonly reported risk factors of PE.[14] All these factors are frequent in AIS patients; yet, no studies have analyzed how they influence the risk of PE specifically in the AIS population. Limited information is available on the impact of PE on stroke outcomes.

The aim of our study was to assess clinical characteristics, risk factors, and relevant clinical outcomes in patients who developed a PE within 30 days after an AIS.

Methods

We collected data from the Registry of the Canadian Stroke Network (RCSN). The RCSN is a clinical database of consecutive

acute stroke patients admitted to 12 stroke centers in Ontario, Canada from July 1, 2003 to June 30, 2008 that has been collected for the purposes of monitoring quality of stroke care.

Study Design and Data Collection

Patients aged 18 years and older with an AIS were included in this analysis. For the purpose of this study, we excluded patients missing a unique health identifier (n=1518) and those with a transient ischemic attack (TIA) (n=268) or hemorrhagic stroke (n=290) as these represent distinct populations. Details of the RCSN can be obtained from http://www.rcsn.org. The cause of poststroke mortality was obtained through linkages of the Ontario Registered Persons Database (RPDB) at the Institute for Clinical Evaluative Sciences. The RPDB is a population-based administrative database that includes basic demographic data and date of death, and provides complete follow-up for all residents in the province. Stroke was diagnosed by a physician, and each patient had CT or MRI to confirm diagnosis and rule out other causes of stroke. We recorded demographic data as well as clinical variables including vascular risk factors, past medical history of chronic obstructive pulmonary disease (COPD), cancer, pulmonary embolism, DVT, prothrombotic state, stroke types, Canadian neurological scale (CNS), iScore,[15,16] and laboratory on arrival. Prothrombotic states, including antiphopholipid antibody syndrome (APA)/lupus anticoagulant, hyperhomocysteinemia, Protein C or S deficiency, Factor V Leiden, and prothrombin gene mutation were identified from laboratory reports or hematology consult. Patients with history of VTE, cryptogenic stroke, or stroke at young age received these investigations. Clinically suspected PE was defined by documented physician diagnosis and confirmed by CT pulmonary angiography within 30 days of admission at hospital.

Outcome Measures

The primary outcome was death or disability at discharge defined as the modified Rankin scale ≥3. Secondary outcomes included disposition status, length of hospital stay (LOS), and death at 3 months and at 1 year.

Statistical Analysis

Chi squared tests were used to compare categorical variables, and analysis of variance (ANOVA) or Kruskal–Wallis tests were used to compare mean and median differences for continuous variables. As differences may be significant but not clinically meaningful, we used standardized differences to compare baseline characteristics between those with and without PE. Standardized differences reflect the mean difference as a percentage of the standard deviation. Effect sizes greater than 0.1 are typically felt to be clinically meaningful.[17] Multivariate logistic regression analysis using backward selection was used to identify variables associated with the occurrence of PE and poor outcomes in ischemic stroke patients. Survival function is represented using Kaplan Meyer curves with differences between groups using the log-rank test. Statistical analysis was performed using SAS statistical software version 9.2.2 (SAS Institute Inc). All tests were 2-tailed, and P values <0.05 were considered significant. Approvals from the St. Michael's Hospital review board and the RCSN Publications Committee were obtained.

Results

Overall, there were 11 287 patients with AIS included in the study. PE within 30 days after admission at hospital was found in 89 (0.78%) patients. AIS patients with PE were most common (53.9%) in the age group ranging 60 to 79 years. Differences in baseline characteristics between stroke patients with and without PE are represented in Table 1. AIS patients with PE were more likely to have history of cancer (29.2% versus 9.9%, P<0.001), previous DVT/PE (10.1% versus 2.7%, P<0.001), and documented prothrombotic state (4.5% versus 0.6%, P<0.001) as compared to patients without PE. Patients with PE were also likely to have a more severe stroke (CNS≤4.5: 30.3% versus 17.6%, P<0.001) and coma 5.6% versus 3.1%, P<0.001). No difference was found in stroke subtypes, iScore, or rates of intravenous recombinant tissue plasminogen activator (rtPA) administration between PE and non-PE groups. DVT during hospitalization was diagnosed in 0.9% of AIS patients without PE and in 36% of stroke patients with PE (P<0.001). DVT, cancer, and prothrombotic state were the only 3 variables with P values <0.05 and standardized differences > 0.1, suggesting that they were clinically meaningful. In the multivariable analysis, age, sex, stroke severity, past history of cancer (OR 3.25, 95% CI 1.94 to 5.45, P<0.0001), past history of DVT/PE (OR 2.41, 95% CI 1.07 to 5.42, P=0.03), and the development of in-hospital DVT (OR 71.3, 95% CI 42.5 to 119.5, P<0.0001) were significant factors associated with PE.

Outcome Measures

Overall, 1446 (12.8%) ischemic stroke patients died during the hospitalization. Higher in-hospital mortality was found in stroke patients with PE (31.5% versus 12.7%, P<0.001). Total death and disability at discharge (mRS≥3) was significantly higher among AIS with PE compared to those without PE (85.4% versus 63.6%, P<0.001) (Table 2, Figure 1). While the mean LOS was 16 days, patients with PE group had longer LOS (36 versus 16 days, P<0.001). AIS patients with PE were also more often discharged to long-term care facilities (21.3%

Table 1. Clinical Characteristics of Patients With and Without PE

	Total (n=11 287), %	Stroke With PE (n=89), %	Stroke Without PE (n=11 198), %	SD	P Value
Age, y					
<60	2063 (18.3)	17 (19.1)	2046 (18.3)	0.02	0.28
60 to 79	5297 (46.9)	48 (53.9)	5249 (46.9)	0.14	
≥80	3927 (34.8)	24 (27.0)	3903 (34.9)	0.17	
Male	5888 (52.2)	46 (51.7)	5842 (52.2)	0.01	0.99
Risk factors					
Diabetes mellitus	2904 (25.7)	19 (21.3)	2885 (25.8)	0.1	0.34
Hypertension	7663 (67.9)	61 (68.5)	7602 (67.9)	0.01	0.9
Hyperlipidemia	3910 (34.6)	23 (25.8)	3887 (34.7)	0.19	0.08
Coronary artery disease	2737 (24.2)	21 (23.6)	2716 (24.3)	0.02	0.89
Atrial fibrillation or atrial flutter	2043 (18.1)	11 (12.4)	2032 (18.1)	0.15	0.16
Congestive heart failure	1062 (9.4)	5 (5.6)	1057 (9.4)	0.13	0.22
Peripheral vascular disease	759 (6.7)	<5	756 (6.8)	0.13	0.21
Asthma or COPD	1426 (12.6)	13 (14.6)	1413 (12.6)	0.06	0.57
Cancer	1138 (10.1)	26 (29.2)	1112 (9.9)	0.64	<0.001
Previous DVT/PE	312 (2.8)	9 (10.1)	303 (2.7)	0.45	<0.001
Prothrombotic state	67 (0.6)	<5	63 (0.6)	0.51	<0.001
Current smoker (last 6 months)	2208 (19.6)	13 (14.6)	2195 (19.6)	0.13	0.24
Preadmission medications					
Antiplatelet therapy	4689 (41.5)	26 (29.2)	4663 (41.6)	0.25	0.02
Anticoagulant therapy	1349 (12.0)	14 (15.7)	1335 (11.9)	0.12	0.27
Preadmission status—independent	8906 (78.9)	66 (74.2)	8840 (78.9)	0.12	0.27
Stroke symptoms					
Aphasia	3823 (33.9)	39 (43.8)	3784 (33.8)	0.21	0.14
Visual field defect	1503 (13.3)	12 (13.5)	1491 (13.3)	0.12	0.47
Dysarthria	4514 (40.0)	29 (32.6)	4485 (40.1)	0.16	0.35
Weakness	9248 (81.9)	73 (82.0)	9175 (81.9)	0.16	0.18
Stroke subtype*				0.45	0.08
Lacunar	1657 (22.1)	5 (8.3)	1652 (22.2)		
Cardioembolic	2889 (38.6)	30 (50)	2859 (38.5)		
Large artery atherosclerosis	1812 (24.2)	12 (20)	1800 (24.2)		
Other	630 (8.4)	8 (13.3)	622 (8.4)		
Undetermined	502 (6.7)	5 (8.3)	497 (6.7)		
Stroke severity on admission				0.42	<0.001
Mild	6279 (55.6)	34 (38.2)	6245 (55.8)		
Moderate	2439 (21.6)	19 (21.3)	2420 (21.6)		
Severe	1995 (17.7)	27 (30.3)	1968 (17.6)		
Coma	348 (3.1)	5 (5.6)	343 (3.1)		
Missing	226 (2.0)	<5	222 (2.0)		

Table 1. Continued

	Total (n=11 287), %	Stroke With PE (n=89), %	Stroke Without PE (n=11 198), %	SD	P Value
Laboratory on arrival, mean±SD					
INR	1.14±0.52	1.24±1.00	1.14±0.52	0.19	0.07
Glucose	7.76±3.41	7.90±3.22	7.76±3.41	0.04	0.7
Thrombolysis therapy					
rtPA intravenous	1737 (15.4)	18 (20.2)	1719 (15.4)	0.14	0.45

Number between brackets indicate percentages, unless otherwise indicated. To preserve patients' identity, cell with number (%) of patients <5 are not reported. *P* value <0.05 significant. COPD indicates chronic obstructive pulmonary disease; DVT, deep venous thrombosis; PE, pulmonary embolism; rtPA, recombinant tissue plasminogen activator; SD, standardized difference.

*Information available: total ischemic stroke, 7490; stroke with PE, 60; stroke without PE, 7430.

versus 10%, $P<0.001$) and rehabilitation institutions (37.7% versus 35.1%, $P<0.001$). Approximately, only 20% of AIS patients with PE were discharged home compared to 43.9% of those without PE ($P<0.001$). In-hospital complications and recurrent stroke within 30 days of admission, including ischemic and hemorrhagic stroke, were significantly more frequent in the PE group (Table 2). Survival curves at 30 days and 1 year after the stroke case index are shown in Figures 2 and 3. In the multivariable analysis, PE (OR 3.02, 95% CI 1.56 to 5.83) was a significant predictor of poor outcome (mRS 3 to 6) (Table 3) and lower survival at 30 days and 1 year (Figures 2 and 3).

Table 2. Outcome Measures

	Total (n=11 287), %	Pulmonary Embolism Group (n=89), %	Non-Pulmonary Embolism Group (n=11 198), %	P Value
Primary outcome				
Death or disability at discharge (mRS≥3)	7196 (63.8)	76 (85.4)	7120 (63.6)	<0.001
Secondary outcomes				
In-hospital complication (within 30 days of admission)				
Cardiac or respiratory arrest	469 (4.2)	16 (18.0)	453 (4.0)	<0.001
Deep vein thrombosis	106 (0.9)	32 (36.0)	74 (0.7)	<0.001
GI hemorrhage	185 (1.6)	7 (7.9)	178 (1.6)	<0.001
Pneumonia	818 (7.2)	22 (24.7)	796 (7.1)	<0.001
Recurrent stroke (within 30 days of admission)				
Hemorrhage	132 (1.2)	<5	129 (1.2)	0.01
Ischemic	313 (2.8)	6 (6.7)	307 (2.7)	0.01
Total	445 (3.9)	9 (10.1)	436 (3.9)	<0.003
Disposition (alive patients only)				
Acute care facility	746 (7.6)	5 (5.6)	741 (7.6)	<0.001
Home	4302 (43.7)	12 (19.7)	4290 (43.9)	
Long-term care facility	991 (10.1)	13 (21.3)	978 (10.0)	
Rehabilitation facility	3454 (35.1)	23 (37.7)	3431 (35.1)	
Other	346 (3.5)	8 (13.1)	338 (3.5)	
Length of hospital stay (days)				
Mean±SD	15.81±23.5	35.82±42.0	15.65±23.2	<0.001
Stroke mortality				
At discharge	1446 (12.8)	28 (31.5)	1418 (12.7)	<0.001
30 days	1549 (13.7)	23 (25.8)	1526 (13.6)	<0.001
1 year	2798 (24.8)	42 (47.2)	2756 (24.6)	<0.001

To preserve patients' identity, cell with number (%) of patients <5 are not reported. *P* value <0.05 significant. mRS indicates modified-Rankin scale; SD, standard deviation.

Figure 1. Functional outcomes based on mRS at discharge in IS with and without PE.
Note: Functional status was not known in 5 (1.1%) patients with PE and 45 (0.4%) patients without PE. IS indicates ischemic stroke; mRS, modified Rankin Scale; PE, pulmonary embolism.

Discussion

In this large cohort study including 11 287 patients with AIS, we found PE in nearly 1% of cases. Patients with PE had higher rates of in-hospital death (almost one-third of patients with PE after AIS died in the hospital) and disability, higher case fatality at 30 days and 1 year, higher prevalence of in-hospital complications, and longer LOS. One-third of stroke patients with PE died during the hospitalization and only 1 in 5 patients were discharged home. PE was a predictor of poor outcomes


Figure 2. Kaplan–Meier curves for 30-day survival in patients with and without PE. Log-rank test <0.0012. PE indicates pulmonary embolism.

Figure 3. Kaplan–Meier curves for 1-year survival in patients with and without PE. Log-rank test <0.0001. PE indicates pulmonary embolism.

Table 3. Multivariate Analysis: Variables Associated With Poor Outcome (mRS 3 to 6) Among Ischemic Stroke Patients

	OR (95% CI)	P Value
Age group, y		
Ref <60	1.0	
60 to 79	1.62 (1.45 to 1.82)	<0.0001
≥80	2.55 (2.25 to 2.90)	<0.0001
Stroke severity on admission		
Mild	1.0	
Moderate	4.37 (3.91 to 4.90)	<0.0001
Severe	12.93 (10.99 to 15.22)	<0.0001
Pulmonary embolism	3.02 (1.56 to 5.83)	0.001

Adjusted for age, sex, stroke severity, history of VTE, and cancer. Only significant variables are presented. P value <0.05 significant. CI indicates confidence interval; mRS, modified-Rankin scale; OR, odds ratio.

after adjusting for age, stroke severity, and other comorbid conditions. Risk factors for PE in stroke patients included age, stroke severity, history of cancer, previous DVT/PE, or development of in-hospital DVT.

The frequency of PE in AIS in our cohort is consistent with previous studies (0.2% to 0.8%).[2,3,18,19] Kelly et al[20] studied venous thromboembolism in AIS patients receiving aspirin and graded compression stockings for thromboprophylaxis and PE in 11.8% of patients. In other studies including cryptogenic stroke and patent foramen ovale, PE was found in up 20% to 37% of patients, though the great majority of these cases were asymptomatic and only recognized by dedicated testing required by the research design.[21,22]

Risk factors of PE in the general population are well known, including age, obesity, immobility, cigarette smoking, hormonal replacement, pregnancy, previous medical illness (particularly PE or DVT, cancer, COPD, hypertension, amd congestive heart failure), stroke with limb paresis, thrombo–philia, and recent surgery.[14] In our AIS cohort we found higher risk of PE among patients with history of cancer or DVT/PE. In addition, DVT during the acute hospitalization had the highest risk of PE. This is not surprising as stroke patients with an acute DVT during hospitalization are the ones at the highest risk. We found no difference in the distribution of stroke subtypes between patients with and without PE. Similar to other reports, we found AIS patients with PE had more severe strokes.[20]

In the International Cooperative Pulmonary Embolism Registry (ICOPER)[9] study of clinical outcomes in 2110 patients with acute PE in a general population, the poor prognostic factors included > 70 years, cancer, congestive heart failure, COPD, systolic arterial hypotension, tachypnea, and right-ventricular hypokinesis on echocardiography. Laporte et al[10] reported that the risk of death in patients with acute PE was associated with age >75 years, immobilization because of a neurologic disease, cardiac or respiratory disease, and cancer. Our study found that in patients with AIS complicated by PE, age of > 60 years and moderate-to-severe stroke severity (CNS<7.5) were associated with poor outcomes. In addition, PE was a predictor of poor outcomes after adjusting from relevant covariates.

The in-hospital mortality rate in AIS patients with PE was 31.5% in our study, comparable with previous findings from Taiwan (35.7%)[23] and Germany (46.8%)[2]; both including a

substantially lower absolute number of stroke patients with PE. The 30-day mortality rate of PE in AIS in our cohort was 25.8%, thus higher than the rates reported in association with PE in the general population (8.6% and 17%).[9,10] Long-term mortality of PE in AIS patients (47.2%) was also higher than previous rates reported in cohorts of PE patients from the general population (24%).[11] It is noteworthy that barely 1 in 2 stroke patients with PE were alive at 1 year in our cohort.

PE is a potentially preventable complication after stroke. A review article suggests the coexistence of PE and pneumonia or PE misdiagnosed as pneumonia due to common risk factors and clinical presentations. PE accounts for the largest proportion of early death, highlighting the importance of thrombo-prophylaxis.[24] More recently, thromboprophylaxis has become one of the quality measures in acute stroke care.[25] Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) reduce VTE after AIS.[26,27] The Clots in Legs Or sTockings after Storke (CLOT) 3 study reported the intermittent pneumatic compression reducing the risk of DVT in AIS with immobility.[28] The American Heart Association/American Stroke Association,[29] Canadian best practice recommendations for stroke care,[30] and the American College of Chest Physicians[31] clinical guideline for ischemic stroke management recommend prophylactic LMWH or UFH be administered to all immobilized patients with an absence of contraindications. In patients who cannot receive anticoagulants for DVT prophylaxis, the use of aspirin and intermittent external compression devices are reasonable.[29]

Our study has some strengths and limitations that deserve comment. First, we had no information on factors that may have affected the risk of PE (eg, time to first mobilization, time of antithrombotics use). Second, we had limited information about the performance status of patients with cancer. Third, it is possible that the lack of association between some variables (eg, stroke subtype) could be due to the limited statistical power. Finally, information on the treatment during hospitalization for stroke patients with PE was not available. Despite these limitations, our study provides relevant information about specific risk factors for PE and the impact of PE on stroke outcomes. Other strengths include a large sample size, the adjustment for relevant covariates including stroke severity, and the near complete follow-up of the patients.

In summary, PE is an uncommon but serious medical complication after an AIS. PE after stroke is associated with higher risk of death, worse disability, higher in-hospital complications, and longer LOS. Our findings highlight the importance of ensuring compliance with thromboprophylaxis measures and guideline recommendations for patients with AIS.[29–31] The risk of PE is higher in older patients with more severe strokes, history of cancer or DVT/PE, or DVT during admission. Early recognition of predisposing conditions may help implement strategies for its early detection and the appropriate preventative measures aimed at improving the quality of stroke care.

References

1. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE Jr, Haley EC Jr. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. *Stroke*. 1998;29: 447–453.

2. Heuschmann PU, Kolominsky-Rabas PL, Misselwitz B, Hermanek P, Leffmann C, Janzen RW, Rother J, Buecker-Nott HJ, Berger K; German Stroke Registers Study Group. Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group. *Arch Intern Med*. 2004;164:1761–1768.

3. Tong X, Kuklina EV, Gillespie C, George MG. Medical complications among hospitalizations for ischemic stroke in the United States from 1998 to 2007. *Stroke*. 2010;41:980–986.

4. Hong KS, Kang DW, Koo JS, Yu KH, Han MK, Cho YJ, Park JM, Bae HJ, Lee BC. Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke. *Eur J Neurol*. 2008;15:1324–1331.

5. Finlayson O, Kapral M, Hall R, Asllani E, Selchen D, Saposnik G; Canadian Stroke Network; Stroke Outcome Research Canada (SORCan) Working Group. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. *Neurology*. 2011;77:1338–1345.

6. Bembenek J, Karlinski M, Kobayashi A, Czlonkowska AJ. Early stroke-related deep venous thrombosis: risk factors and influence on outcome. *J Thromb Thrombolysis*. 2011;32:96–102.

7. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med*. 1998;158:585–593.

8. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb Haemost*. 2007;5:692–699.

9. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet*. 1999;353:1386–1389.

10. Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, Monreal M; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. *Circulation*. 2008;117:1711–1716.

11. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE. The clinical course of pulmonary embolism. *N Engl J Med*. 1992;326:1240–1245.

12. Skaf E, Stein PD, Beemath A, Sanchez J, Olson RE. Fatal pulmonary embolism and stroke. *Am J Cardiol*. 2006;97:1776–1777.

13. Ingeman A, Andersen G, Hundborg HH, Svendsen ML, Johnsen SP. In-hospital medical complications, length of stay, and mortality among stroke unit patients. *Stroke*. 2011;42:3214–3218.

14. Goldhaber SZ. Pulmonary embolism. *Lancet*. 2004;363:1295–1305.

15. Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, Tu JV, Mamdani M, Austin PC; Investigators of the Registry of the Canadian Stroke Network; Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. *Circulation*. 2011;123:739–749.

16. Saposnik G, Raptis S, Kapral MK, Liu Y, Tu JV, Mamdani M, Austin PC; Investigators of the Registry of the Canadian Stroke Network and the Stroke Outcome Research Canada Working Group. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. *Stroke*. 2011;42:3421–3428.

17. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. *BMJ*. 2005;330:960–962.

18. Skaf E, Stein PD, Beemath A, Sanchez J, Bustamante MA, Olson RE. Venous thromboembolism in patients with ischemic and hemorrhagic stroke. *Am J Cardiol*. 2005;96:1731–1733.

19. Tirschwell DL, Kukull WA, Longstreth WT Jr. Medical complications of ischemic stroke and length of hospital stay: experience in Seattle, Washington. *J Stroke Cerebrovasc Dis*. 1999;8:336–343.

20. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thrombo-embolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. *Stroke*. 2004;35:2320–2325.

21. Allendörfer J, Tanislav C, Puille M, Grebe M, Stolz E, Jauss M. Risk factors for pulmonary embolism in patients with stroke and patent foramen ovale. *Cerebrovasc Dis*. 2007;24:138–139.

22. Tanislav C, Puille M, Pabst W, Reichenberger F, Grebe M, Nedelmann M, Kaps M, Allendörfer J. High frequency of silent pulmonary embolism in patients with cryptogenic stroke and patent foramen ovale. *Stroke*. 2011;42: 822–824.

23. Chen CC, Lee TH, Chung CY, Chang WH, Hong JP, Huang LT, Tang SF, Chen CK. Symptomatic pulmonary embolism among stroke patients in Taiwan: a retrospective cohort study. *Top Stroke Rehabil*. 2012;19:361–368.

24. Kelly J, Hunt BJ, Rudd A, Lewis RR. Pulmonary embolism and pneumonia may be confounded after acute stroke and may co-exist. *Age Ageing*. 2002;31: 235–239.

25. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E, Labresh KA. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. *Circulation*. 2009;119:107–115.

26. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. *Ann Intern Med*. 2011;155:602–615.

27. Kamphuisen PW, Agnelli G. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? *Thromb Res*. 2007;119:265–274.

28. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. *Lancet*. 2013;382:516–524. Available at: http://dx.doi.org/10.1016/S0140-6736(13)61050-8.

29. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2013;44:870–947.

30. Lindsay MP, Gubitz G, Bayfey M, Philips S. Canadian Best Practice Recommendations for Stroke Care. Available at: http://www.strokebestprac-tices.ca. Accessed May 27, 2013.

31. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, Sonnenberg FA, Schulman S, Vandvik PO, Spencer FA, Alonso-Coello P, Guyatt GH, Akl EA; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 suppl):e601S–e636S. doi:10.1378/chest.11-2302.